Fezolinetant

Fezolinetant, sold under the brand name Veozah, among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Fezolinetant, sold under the brand name Veozah, among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause. It is a small-molecule, selective neurokinin-3 (NK 3 ) receptor antagonist taken by mouth. It was developed by Astellas Pharma, which acquired it from Ogeda (formerly Euroscreen) in April 2017.

The most common side effects of fezolinetant include abdominal pain, diarrhea, insomnia, back pain, hot flush, and elevated hepatic transaminases. Fezolinetant was approved for medical use in the United States in May 2023, and it was approved in the European Union in December 2023.

Fezolinetant is the first NK 3 receptor antagonist approved by the US Food and Drug Administration (FDA) to treat moderate to severe hot flashes from menopause. The FDA considers it to be a first-in-class medication. Fezolinetant shows high affinity for and potent inhibition of the NK 3 receptor in vitro (K i = 25 nM, = 20 nM).

Loss-of-function mutations in TACR and TACR3, the genes respectively encoding neurokinin B and its receptor, the NK 3 receptor, have been found in patients with idiopathic hypogonadotropic hypogonadism. In accordance, NK 3 receptor antagonists like fezolinetant have been found to dose-dependently suppress luteinizing hormone (LH) secretion, though not that of follicle-stimulating hormone (FSH), and consequently to dose-dependently decrease estradiol and progesterone levels in females and testosterone levels in males.

As such, they are similar to GnRH modulators, and present as a potential clinical alternative to them for use in the same kinds of indications. However, the inhibition of sex hormone production by NK 3 receptor inactivation tends to be less complete and "non-castrating" relative to that of GnRH modulators, and so they may have a reduced incidence of menopausal-like side effects such as loss of bone mineral density.

Unlike GnRH modulators, but similarly to estrogens, NK 3 receptor antagonists including fezolinetant and MLE-4901 (also known as AZD-4901, formerly AZD-2624) have been found to alleviate hot flashes in menopausal females. This would seem to be independent of their actions on the hypothalamic–pituitary–gonadal axis and hence on sex hormone production.

NK 3 receptor antagonists are anticipated as a useful clinical alternative to estrogens for management of hot flashes, but with potentially reduced risks and side effects. The effectiveness of Veozah to treat moderate to severe hot flashes was demonstrated in each of the first 12-week, randomized, placebo-controlled, double-blind portions of two phase III clinical trials.

In both trials, after the first 12 weeks, the females on placebo were then re-randomized to Veozah for a 40-week extension study to evaluate safety. Each trial ran a total of 52 weeks. The average age of the trial participants was 54 years old.

The FDA granted the application for fezolinetant priority review designation. The approval of Veozah was granted to Astellas Pharma US, Inc.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1352104843 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

17 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.